flufenamic acid has been researched along with Epilepsy in 4 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 5.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 1.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Hernández-Martín, N | 1 |
| Gomez, F | 1 |
| Silván, Á | 1 |
| Rosa, RF | 1 |
| Delgado, M | 1 |
| Bascuñana, P | 1 |
| Pozo, MÁ | 1 |
| García-García, L | 1 |
| Fernández, M | 1 |
| Lao-Peregrín, C | 1 |
| Martín, ED | 1 |
| Schiller, Y | 1 |
1 review available for flufenamic acid and Epilepsy
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
3 other studies available for flufenamic acid and Epilepsy
| Article | Year |
|---|---|
A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Epilepsy; Epilepsy, Temporal Lobe; Flufen | 2023 |
Flufenamic acid suppresses epileptiform activity in hippocampus by reducing excitatory synaptic transmission and neuronal excitability.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non | 2010 |
Activation of a calcium-activated cation current during epileptiform discharges and its possible role in sustaining seizure-like events in neocortical slices.
Topics: Animals; Calcium; Cations; Electric Conductivity; Electrophysiology; Epilepsy; Flufenamic Acid; In V | 2004 |